ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.07) by 785.71 percent. This is a 313.33 percent decrease over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $44.206 million which beat the analyst consensus estimate of $43.069 million by 2.64 percent. This is a 167.64 percent increase over sales of $16.517 million the same period last year.